Constitutive activation of Wnt/b-catenin signaling in cancer results from mutations in pathway components, which frequently coexist with autocrine Wnt signaling or epigenetic silencing of extracellular Wnt antagonists. Among the extracellular Wnt inhibitors, the secreted frizzled-related proteins (SFRPs) are decoy receptors that contain soluble Wnt-binding frizzled domains. In addition to SFRPs, other endogenous molecules harboring frizzled motifs bind to and inhibit Wnt signaling. One of such molecules is V3Nter, a soluble SFRP-like frizzled polypeptide that binds to Wnt3a and inhibits Wnt signaling and expression of the b-catenin target genes cyclin D1 and c-myc. V3Nter is derived from the cell surface extracellular matrix component collagen XVIII. Here, we used HCT116 human colon cancer cells carrying the DS45 activating mutation in one of the alleles of b-catenin to show that V3Nter and SFRP-1 decrease baseline and Wnt3a-induced b-catenin stabilization. Consequently, V3Nter reduces the growth of human colorectal cancer xenografts by specifically controlling cell proliferation and cell cycle progression, without affecting angiogenesis or apoptosis, as shown by decreased [ 
Introduction
The Wnt/b-catenin pathway is a major regulator of cell proliferation, migration, differentiation and metabolism, controlling tissue homeostasis and tumor progression (MacDonald et al., 2009) . In the majority of colorectal cancers (CRC), the coexistence of several mechanisms such as genetic defects in pathway components, autocrine Wnt signaling and epigenetic silencing of extracellular Wnt antagonists results in activation of Wnt/b-catenin signaling and provides a selective advantage to tumor cells (Polakis, 2007) . Pathway activation involves interaction of Wnt ligands with cell surface Frizzled receptors and LRP5/6 co-receptors. This disrupts the Adenomatous polyposis coli (APC)-axin complex, thus halting proteasomal degradation of b-catenin, which is stabilized and interacts with T-cell factor transcription factors, displacing repressors and recruiting activators of target gene expression.
The activity of the Wnt/b-catenin pathway can be antagonized by several families of secreted proteins. Interaction of Wnt ligands with the Frizzled receptors is enhanced by heparan sulfate glycosaminoglycans controlling Wnt diffusion at the cell surface (Mikels and Nusse, 2006) or inhibited by several families of extracellular antagonists (Kawano and Kypta, 2003; Bovolenta et al., 2008) . Members of the Dickkopf (DKK) family antagonize canonical signaling by binding to LRP5/6, thus disrupting the Wnt-induced Frizzled-LRP5/6 complex (MacDonald et al., 2009) . Wnt inhibitory factor-1 binds directly to Wnts, altering their ability to interact with the receptors. Members of the family of extracellular decoy receptors known as secreted frizzled-related proteins (SFRPs) possess a frizzled cysteine-rich domain (CRD) structurally similar to the extracellular Wnt-binding domain of the frizzled receptors. Frizzled CRDs contain 10 cysteines at conserved positions, which form a highly conserved three-dimensional structure through a precise pattern of disulfide bridges. Frizzled CRDs bind Wnts and form homodimers or heterodimers (Dann et al., 2001) . Thus, SFRPs can modulate Wnt signaling by sequestering Wnts through the CRD or by acting as dominantnegative inhibitors, forming inactive complexes with the frizzled receptors (Bovolenta et al., 2008) . In addition, engineered SFRP-like proteins such as the soluble CRD of the receptor Frizzled 8 potently inhibit autocrine Wnt signaling and tumor growth in mice carrying teratomas (DeAlmeida et al., 2007) .
It has been suggested that SFRPs may function as tumor suppressors in CRC because allelic loss or epigenetic inactivation of SFRP genes contributes to constitutive activation of the Wnt/b-catenin pathway (Caldwell et al., 2004; Suzuki et al., 2004) . In this context, we and others have shown that restoring expression of SFRP-1 or SFRP-5 inhibits Wnt/b-catenin stabilization and induces in vitro cell death in human CRC cells (Suzuki et al., 2004; Quelard et al., 2008) . In addition to SFRPs, other endogenous molecules carrying frizzled CRDs bind to and inhibit Wnt signaling. We recently showed that a frizzled CRD derived from cell surface collagen XVIII (C18) functions in an SFRP-like fashion, binding to Wnt3a and inhibiting Wnt/b-catenin signaling in vitro (Quelard et al., 2008) . C18 is expressed as three alternative tissue-specific variants, differing in their N-terminal (Nter) noncollagenous domains ( Figure 1a ), which are generated by two alternative promoters and mRNA splicing (Muragaki et al., 1995; Rehn et al., 1996) . Variant 1 is a ubiquitous structural basement membrane component (Saarela et al., 1998) . Variant 2 (V2) is a plasma protein produced mainly in the liver (Musso et al., 2001) . Variant 3 (V3) is expressed at very low levels during Xenopus embryogenesis (Elamaa et al., 2002) , in human fetal (Elamaa et al., 2003) , normal adult and tumor liver tissues (Quelard et al., 2008) , and is not detected in metastatic CRCs (Musso et al., 2001) . Proteolytic processing of V3 releases V3Nter, an aminoterminal glycoprotein containing a frizzled CRD, which locates at the cell surface in cancer cells and matches the three-dimensional structures of frizzled 8 and SFRP-3 CRDs (Quelard et al., 2008) .
These findings led us to explore the potential inhibitory effects of the frizzled module of C18 on tumor growth. We show here that V3Nter and SFRP-1 attenuate baseline and Wnt3a-induced b-catenin stabilization in HCT116 cells, reducing in vitro and in vivo tumor growth through slowed cell cycle progression. Moreover, V3Nter inhibits Wnt3a-induced b-catenin signaling in allele-targeted HCT116 cells carrying either wild-type (WT) or mutant b-catenin, confirming that V3Nter blocks tumor growth in the context of constitutively activated b-catenin.
Results

HCT116 colorectal cancer cells stably expressing V3Nter
or SFRP-1 show low b-catenin levels We produced HCT116 cell cultures stably expressing V3Nter (V3Nter-HCT116) or SFRP-1 (SFRP-1-HCT116) (Figures 1a and b) . As negative controls, we prepared cells expressing either the homologous C18 polypeptide lacking the frizzled module (V2Nter-HCT116) or empty pCDNA3.1 vector (Vector-HCT116, Figures 1a and b) . In HCT116 cells, transient expression of V3Nter, SFRP-1 or SFRP-5 induces cell death (Suzuki et al., 2004; Quelard et al., 2008) . Consistently, attempts to obtain clones by limiting dilution were unsuccessful, suggesting a negative selection pressure, as shown for SFRP-1 in breast cancer cells (Bafico et al., 2004) . However, after seeding three cells per well, several antibiotic-resistant cell populations expressing the relevant epitopes (Supplementary Figure 1a) were expanded. By immunocytochemistry, they were composed of B50% of cells expressing high levels of V3Nter or SFRP-1 and low b-catenin levels, and B50% of cells showing low V3Nter or SFRP-1 content and high b-catenin levels (Figure 1c ). In V3Nter (-) cells neighboring V3Nter ( þ ) foci, b-catenin was restricted to cell membranes and particularly to cell contacts ( Figure 1c , close-up), suggesting paracrine inhibition of Wnt/b-catenin signaling. Controls, that is, Vectorand V2Nter-HCT116 cells, showed widespread high b-catenin levels ( Figure 1c ). These features were stably maintained at least throughout 15 passages.
Consistently with our recent report using transient expression experiments (Quelard et al., 2008) , b-catenin-T-cell factor-regulated transcription (CRT) and cyclin D1 promoter activity were significantly decreased in HCT116 cells stably expressing V3Nter or SFRP-1, in contrast to cells expressing V2Nter or empty vector ( Supplementary Figures 1b and c) . Similar effects on CRT were obtained with two different stable V3Nter cell batches (Supplementary Figure 1d) .
Paracrine inhibition of Wnt3a-induced b-catenin stabilization in HCT116 cells V3Nter attenuated CRT in a dose-response assay to soluble Wnt3a (Figure 2a ). In contrast, V2Nter enhanced CRT in this context (Figure 2a) . Indeed, heparan sulfates attached to the 47-aa stretch common to the three C18 variants (Figure 1b ) may locally increase Wnt concentration and thus CRT, as shown for C18 (Quelard et al., 2008) and for other heparan sulfate proteoglycans (Mikels and Nusse, 2006) . Accordingly, the slope of the Wnt3a dose-response curve for V2Nter-HCT116 cells was steeper than that of the other cells, including Vector-HCT116 cells. In contrast, V3Nter-HCT116 cells reached the maximal CRT under a 25% dilution of Wnt3a-conditioned medium, and further increases in Wnt3a concentration had no effect on CRT (Figure 2a ). Immunoblot showed that basal and Wnt3a-induced levels of total b-catenin were lower in V3Nter-and SFRP-1-HCT116 cells than in Vector-or V2Nter-HCT116 cells (Figure 2b ). These findings suggested that cell surface V3Nter could decrease b-catenin stabilization and transcriptional activity in response to soluble Wnt3a. Although soluble V3Nter and FZC18 (frizzled domain of collagen XVIII) are detected in the conditioned medium at low levels, the bulk of the secreted proteins remain as cell surface forms (Quelard et al., 2008) . Therefore, FZC18-expressing cells might impact on the microenvironment of adjacent cells, thereby modulating their response to Wnt stimuli. To check this hypothesis, we cocultured human embryonic kidney 293 (HEK293) cells stably expressing the frizzled domain of C18 (FZC18-HEK cells) with parental HCT116 cells expressing the CRT reporters. Cocultures were established at different ratios of FZC18 ( þ ) cells to a constant number of HCT116 reporter cells in the presence of 50% Wnt3a-conditioned medium. Thus, the CRT response of HCT116 cells to soluble Wnt3a was inversely proportional to the number of FZC18 ( þ ) cells (Figure 2c ). These findings confirm that V3Nter exerts its biological effects in the extracellular space. Figure  2d) . Taken together, these data show that expression of V3Nter inhibits soluble Wnt3a-induced b-catenin signaling in parental HCT116 cells (DS45/WT bcatenin), as well as in allele-targeted cells carrying either WT or mutant b-catenin. Inhibition is, however, most efficient in cells carrying only the WT allele, suggesting that, in parental HCT116 cells, the decrease in Wnt signaling results from the additive effects on both alleles of b-catenin. Consistently, in human CRC cells, phosphorylation of b-catenin at S45 does not seem to be required for subsequent phosphorylation at residues S33, S37 or T41, in contrast to the prevailing models in normal cells . However, S33 and S37 are essential for interaction with b-TrCP and subsequent b-catenin ubiquitination and degradation (Hart et al., 1999) . Therefore, as expected, in HEK293T cells transiently expressing S37A b-catenin or a dominantnegative form of b-catenin lacking the S33, S37, T41 and S45 residues (D29-48 b-catenin), neither V3Nter nor SFRP-1 could inhibit CRT (not shown). Further experiments using FZC18 or SFRP-5 confirmed these findings (not shown).
V3Nter or SFRP-1 cDNAs inhibited the CRT increase induced by transiently expressed WT, S33Y or S37A b-catenins in Huh-7 human liver cancer cells carrying endogenous WT b-catenin (Figure 3d Below, total protein extracts from these cells were immunoblotted with anti-myc epitope tag detecting FZC18. The same blot was probed with anti-GAPDH as a loading standard.
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V3Nter reduces tumor cell proliferation in vitro through slowed cell cycle progression Time course of [ 3 H]-thymidine incorporation into newly synthesized DNA in response to serum stimulation showed a twofold decrease in DNA synthesis in V3Nter-and in SFRP-1-HCT116 cells (Figure 4a) . A different batch of V3Nter cells confirmed these data (Supplementary Figure 3a) . These findings were further confirmed by analysis of mitochondrial succinate dehydrogenase activity (MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay) in a 96-h time course.
In addition, this test showed no differences in cell survival at 24 h after plating (Supplementary Figure 3b) . Consistently, a low apoptotic rate over a 72-h time course was observed in HCT116 cells stably expressing V3Nter, SFRP-1 or V2Nter, as assessed by quantification of the subG1 population of cells by flow cytometry (Supplementary Figure 3c ). Cell cycle analysis indicated that expression of V3Nter and SFRP-1 resulted in accumulation of cells in G0/G1 phase and a decrease in S-phase cells (Figure 4b) .
Clonogenesis assays showed no difference in colony number between V3Nter or SFRP-1 and Vector-HCT116 cells (Figure 4c, Supplementary Figure 4a ), but V2Nter plates contained B20% more colonies than Vector or V3Nter plates (Supplementary Figure 4a) . This finding is consistent with the enhanced CRT in V2Nter cells shown above ( Figure 2c ) and with the 20% increase in clonogenesis that we previously showed in HCT116 cells expressing V2Nter (Quelard et al., 2008) . Interestingly, V3Nter-HCT116 cells showed reduced colony size with respect to Vector-and V2Nter-HCT116 cells (Figures 4c and d, Supplementary Figure  4b ). Small colonies (1-1.5 mm in diameter) represented 65% of V3Nter-and 35% of SFRP-1-HCT116 colonies, but only 25% of Vector-HCT116 ones. Conversely, large colonies (3-4 mm in diameter) represented 30% of Vector-and 2% of V3Nter-or 10% of SFRP-1-HCT116 ones. In V3Nter-HCT116 plates, small colonies arose more frequently than in V2Nter-HCT116 plates. Together with the above observations, that is, reduced cyclin D1 promoter activity and reduced DNA synthesis, but good cell viability, these findings suggest an inhibition on tumor cell proliferation rather than an effect on plating efficiency or viability. A similar profile was described in HCT116 cells after inhibition of cyclin D1 expression by a dominant-negative T-cell factor (Tetsu and McCormick, 1999) . An SFRP-like frizzled motif blocks tumor growth E Lavergne et al V3Nter inhibits in vivo tumor growth through decreased cell proliferation Xenografts of V3Nter-HCT116 cells in nude mice showed that V3Nter delayed tumor onset. More than 90% of the mice injected with Vector-HCT116 cells developed a solid tumor at day 13, whereas only 60% of the V3Nter-HCT116 cell-injected mice had a tumor on day 25 (Figure 5a ). In addition, growth of V3Nter-expressing tumors was significantly reduced. On day 22, the mean volume of these tumors was sevenfold smaller than that of the Vector-HCT116 tumors (Figures 5b and  c, Supplementary Figure 5a) . Two batches of V3Nter-HCT116 cells showed a similar growth pattern (Supplementary Figure 5b ). SFRP-1 delayed tumor onset to a lesser extent. Indeed, 70% of the SFRP-1-HCT116 cellinjected mice had a tumor on day 17 and 100% on day 25. On day 22, SFRP-1 reduced tumor growth by 2.2-fold, with respect to empty-vector-expressing HCT116 cells. Tumor onset and growth of V2Nter-and Vector-HCT116 cells were not significantly different ( Figures  5a-c, Supplementary Figure 5a) . Throughout the experiment, V3Nter-HCT116 tumors expressed V3Nter, as shown by immunostaining at day 20 after subcutaneous injection (Supplementary Figure 6a) .
Magnetic resonance imaging in representative living mice revealed that the rapid growth curve of Vector-HCT116 tumors was associated with important hemorrhagic necrosis, which was not observed in V3Nter-HCT116 tumors (Figure 5d ). T2-weighted signal showed large necrohemorrhagic foci in Vector-HCT116 (day 14) but a very small focus in V3Nter-HCT116 (day 18) tumors ( Figure 5d ), which was confirmed by anatomic pathology tumor analysis after killing the mice (data not shown).
We assessed cell proliferation, microvessel density and apoptosis in situ in V3Nter-HCT116 tumors by immunostaining with anti-BrdU, anti-CD31 or by the TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay. Because in vivo labeling of S-phase cells with BrdU is influenced by tissue perfusion (Kyle et al., 2003) , we intravenously administered carbocyanine as a marker of functional blood vessels and searched for S-phase cells at any point p200 mm from a carbocyanine-positive vessel.
As the growth kinetics of V3Nter-HCT116 cell tumors was different from that of control groups (Figure 5c (c) HCT116 cells stably transfected with the indicated expression vectors were seeded at low density and cultured for 14 days. After paraformaldehyde fixing and hematoxylin staining, colonies (seen as dark spots) were digitized using a video camera. (d) After printing photographs of colony-containing dishes, colonies were measured, assigned to size categories and blindly counted using a grid. Histograms represent distribution of cells in each category of colony size (mean ± s.d. from three replications). V3Nter-HCT116 colonies are significantly smaller than Vector-or V2Nter-HCT116 colonies. Statistical analysis is shown in Supplementary Figure 4b .
An SFRP-like frizzled motif blocks tumor growth E Lavergne et al HCT116 with respect to Vector-HCT116 cell tumors ( Figure 6 ). To confirm these data, we immunostained cryosections derived from six additional tumors (Vectoror V3Nter-HCT116 tumors) with Ki67, a marker expressed on all proliferating cells during late G1, S, M and G2 phases of the cell cycle ( Supplementary  Figures 6b and c) . Consistently, the number of Ki67-positive cells was reduced in V3Nter-HCT116 tumors compared with control ones. TUNEL assay, assessing DNA fragmentation, revealed no significant differences between the number of apoptotic cells in control and V3Nter-expressing tumors ( Figure 6 ). Similarly, we observed no variation in microvessel density between Vector-and V3Nter-expressing tumors (Figure 6 ). Taken together, these findings indicate that V3Nter expression delays tumor growth, profoundly changing the growth kinetics of HCT116 CRC cells in vivo.
V3Nter-expressing tumors exhibit a switched off Wnt/ b-catenin gene expression signature To determine whether V3Nter affected the expression of Wnt/b-catenin target genes, we obtained genome-wide expression profiles of Vector and V3Nter tumors and tested their enrichment in Wnt signaling gene expression signatures using gene set enrichment analysis (GSEA). GSEA evaluates microarray data, focusing on previously published gene sets sharing common biological function (Subramanian et al., 2005) . Gene sets were derived from two independent and curated Wnt activation signatures: loss of APC in vivo in the mouse intestine (Sansom et al., 2004) and expression of a constitutively active mutant b-catenin by mammary cells (Kenny et al., 2005) . GSEA demonstrated that Vector and V3Nter gene expression profiles were respectively enriched in up-and downregulated Wnt/b-catenin targets (Figure 7a , Po0.05). Consistently, microarray analysis revealed that V3Nter significantly reduced the expression of the b-catenin targets Survivin, EpCAM, MMP-9, c-myc and Wnt3 among other genes (Figure 7b ).
Discussion
The development of extracellular Wnt inhibitors working in the context of b-catenin pathway mutations is a promising therapeutic strategy. Enhanced autocrine Wnt signaling (Bafico et al., 2004) and epigenetic silencing of genes encoding endogenous extracellular Wnt inhibitors (Suzuki et al., 2004) provide a positive selection advantage to cells carrying b-catenin pathway mutations (Barker and Clevers, 2006; Polakis, 2007; MacDonald et al., 2009) . In this setting, frizzled receptor activation and enhanced Wnt expression drive positive cancer cell selection (Vider et al., 1996 ; Smith et al., An SFRP-like frizzled motif blocks tumor growth E Lavergne et al 1999; Dimitriadis et al., 2001; Holcombe et al., 2002; Ueno et al., 2008) . Consequently, extracellular Wnt inhibitors such as SFRPs (Taketo, 2004) , Wnt inhibitory factor-1 (Hu et al., 2009) or anti-Wnt1 antibodies (He et al., 2005) block tumor cell growth in cells carrying mutant b-catenin.
In this work, we show that expression of a collagenderived frizzled domain inhibits Wnt3a-induced b-catenin stabilization in HCT116 cells. V3Nter (À) cells neighboring V3Nter ( þ ) foci showed low cytoplasmic and nuclear b-catenin content, suggesting that V3Nter could impact on the cell microenvironment. This notion was supported by paracrine inhibition of Wnt3a-induced CRT in cocultures of FZC18-expressing normal cells with parental HCT116 cells, indicating that the frizzled domain of C18 can inhibit Wnt signaling in the extracellular space.
V3Nter was unable to affect CRT in SW480 cells, which cannot degrade b-catenin, as they lack functional APC (Yang et al., 2006) . Similarly, neither V3Nter nor SFRP-1 affected CRT in cancer cell lines carrying WT b-catenin. These findings suggest that the effects of V3Nter are specific to the Wnt/b-catenin pathway.
A previous report showed that SFRP-1 had no effect on growth of HCT116 cells in vivo (Bafico et al., 2004) . In that work, the authors used allele-targeted HCT116 cells carrying only WT b-catenin that exhibited elevated basal-level CRT, as well as higher response to serum growth factors and tumor growth than parental cells (Sekine et al., 2002) . In contrast, the WT b-catenin clone used here showed no measurable CRT and the in vivo growth of parental, mutant and WT HCT116 cells were not significantly different (Chan et al., 2002) , which probably explain the contrasting results.
We show that DS5 b-catenin does not completely abrogate inhibition of Wnt signaling by SFRP-like frizzled domains. Indeed, in colon cancer cells, priming phosphorylation at S45 of b-catenin does not seem to be required for subsequent phosphorylation of upstream residues S33, S37 and T41 . Therefore, in parental HCT116 cells, inhibition of Wnt signaling results from the additive effects on both WT and mutant b-catenin alleles. As serines 33 and 37 of b-catenin are essential for b-TrCP-dependant b-catenin degradation (Hart et al., 1999) , neither V3Nter nor SFRP-1 inhibited CRT in HEK293T cells expressing mutant S33 or S37 b-catenins, implying a GSK3b-and b-TrCP-dependent pathway. In contrast, in human liver cancer cells expressing either S37A or S33Y b-catenins, SFRP-1 and V3Nter did inhibit CRT, suggesting a GSK3b and b-TrCP-independent pathway. An SFRP-like frizzled motif blocks tumor growth E Lavergne et al
An increasing body of evidence Suzuki et al., 2004; He et al., 2005) indicates that the mechanism of b-catenin degradation may be different in cancer cells with respect to normal cells (Liu et al., 2002) , supporting the notion that b-TrCP-independent pathways could be alternatively involved. Indeed, the ubiquitination of b-catenin by different E3 ligases that can bypass b-catenin phosphorylation occurs in specific contexts. For example, b-catenin can be degraded by Jade-1 (Chitalia et al., 2008) , Siah-1 or other ubiquitin ligases (Dimitrova et al., 2010) . Therefore, although the major mechanism of regulation of b-catenin activity is phosphorylation, the Wnt pathway may use multiple ways to regulate the concentration of b-catenin (Tolwinski and Wieschaus, 2004; Salahshor and Woodgett, 2005) .
By GSEA, V3Nter-expressing tumors presented a switched off Wnt/b-catenin gene expression signature, further confirming inhibition of Wnt/b-catenin signaling and downstream gene expression. Among the switched off genes, MMP-9 is involved in local invasion and metastasis (Takeuchi et al., 2004) , being secreted by macrophages and tumor infiltrating lymphocytes, as well as by CRC cells (Ahmed et al., 2003) . Survivin and c-myc are key regulators of cell growth in most human cancers and unfavorable prognostic markers, inhibiting cell death induced by several anticancer agents (Mita et al., 2008; Albihn et al., 2010) . The epithelial cell adhesion molecule EpCAM is involved in a positive regulatory loop of Wnt signaling (Munz et al., 2009) .
We present compelling in vitro and in vivo data showing that a collagen-derived frizzled domain specifically blocks tumor cell growth through decreased cell proliferation and slowed cell cycle progression. V3Nter had a major impact on the growth kinetics of tumors. Similarly, magnetic resonance imaging in living mice revealed that V3Nter-expressing tumors had minimal tumor necrosis with respect to the massive central necrosis seen in control HCT116 tumors. Spontaneous tumor necrosis is a hallmark of CRC, resulting in ominous clinical complications (Treanor and Quirke, 2007) . It is the consequence of an insufficient vascular support to cope with rapid cell proliferation in fast growing tumors (Ramanujan et al., 2000) . As inhibition of Wnt signaling slowed tumor growth, it restored the appropriate ratio of vascular support to tumor burden, thereby dramatically reducing necrosis. In conclusion, we show that an SFRP-like frizzled domain inhibits tumor growth in CRC. Its potential to attenuate cell growth and to sensitize to apoptosis may contribute to new combined and personalized therapies that take into account the status of downstream b-catenin pathway components.
Materials and methods cDNAs
V2Nter, V3Nter and SFRP-1 cDNAs, the Super8TOP and Super8FOP Flash reporters, the Cyclin D1 promoter reporter D1D-944pXP2, WT b-catenin and the normalization Renilla luciferase vector pGL4.70[hRluc] were previously described (Quelard et al., 2008) . S37A and D29-48 b-catenins were kindly provided by Y. Yang (Topol et al., 2003) . Vectors pcDNA3-S33Y b-catenin (Addgene plasmid 19286; (Kolligs et al., 1999) ) and pCMV-Neo-Bam APC (Addgene plasmid 16507; (Morin et al., 1997) ) were provided by E Fearon and K Kinzler, respectively.
Mice and tumors
Female athymic nude (nu/nu) mice were obtained from Iffa Credo (Charles River, l'Arbresle, France), housed under specific pathogen-free conditions and used for experiments at 6 weeks of age. All animal experimental procedures were carried out using Institutional Animal Care-approved protocols. Mice received 3 Â 10 6 tumor cells by subcutaneous injection in both hind legs in 100 ml serum-free medium. Tumor size was measured three times a week with a digital caliper, and tumor volume was estimated from the following An SFRP-like frizzled motif blocks tumor growth E Lavergne et al formula: width Â length Â (width þ length)/2. Mice were killed when the tumor volume reached B1200 mm 3 or as indicated. Tumors were excised, snap frozen in liquid-nitrogen-cooled isopentane and stored at À80 1C.
The BrdU incorporation assay was performed as described (Kyle et al., 2003) . Briefly, 20 days after tumor injection, BrdU (Sigma, Steinheim, Germany) was administered intraperitoneally 2 h before killing as a 50 mg/ml solution in saline at a dose of 1500 mg/kg. As a marker of tissue perfusion, mice were intravenously administered B75 ml of 0.6 mg/ml carbocyanine (Invitrogen, Carlsbad, CA, USA) in 75% DMSO solution 5 min before killing.
Gene expression profiling and GSEA After histological analysis and homogeneization of B400 mm 3 of representative tumor tissue, RNA was extracted from Vector (n ¼ 3 tumors from three inoculation points from three mice) and V3Nter (n ¼ 6 tumors from six inoculation points from three mice). V3Nter tumors excised from the same mice were pooled. Total RNA was isolated by the guanidinium thiocyanate/cesium chloride method followed by a second extraction of the CsCl pellet with the NucleoSpin RNA II kit (Macherey-Nagel, Du¨ren, Germany). In vitro transcription and labeling of 150 ng total RNA was carried out using an Agilent Low-Input QuickAmp Labeling kit (Agilent Technologies, Santa Clara, CA, USA) in the presence of Cy3-CTP following the manufacturer's protocol. After purification using a RNeasy mini kit (Qiagen, Hilden, Germany), cRNA yield and specific activity were determined using a NanoDrop spectrophotometer (yield, 9.2 ± 0.5 mg cRNA; specific activity, 20.0±0.4 pmol Cy3 per mg cRNA). Equal amount (1.65 mg) of Cy3-labeled cRNA was subjected to fragmentation followed by 18-h hybridization onto Agilent human 4 Â 44K v2 pangenomic microarrays, washing and scanning according to the manufacturer's instructions (Agilent Technologies). Gene expression data were further processed using Feature Extraction (version 10.7) and GeneSpring (version 11.0) softwares (Agilent Technologies). Filtration of array data resulted in the selection of 17 902 nonflag-positive and significant gene features. Interarrays normalization was performed by using the 75th percentile signal value. GSEA was performed by using the web-based tool developed at the Broad Institute (Subramanian et al., 2005) , as previously described (Coulouarn et al., 2009) . Specific Wnt signatures (Sansom et al., 2004; Kenny et al., 2005) were retrieved using the curated collection C2 of Molecular Signatures Database (MSigDB, web-based tool developed by the Broad Institute, Cambridge, MA, USA).
Cell culture, transfection, reporter assays, cell growth assays, immunological methods, image acquisition and analysis, in vivo magnetic resonance imaging and statistical analysis were performed using standard methods. A detailed description is given in the Supplemental Materials and Methods section.
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